| Zhao, Liyuan |
NCT04222114: Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis |
|
|
| Recruiting | 3 | 282 | RoW | Catumaxomab, The treatment of investigator choice | LintonPharm Co.,Ltd. | Stomach Neoplasms | 03/23 | 08/23 | | |
NCT06256562: A Study of GZR18 Injection in Obese/Overweight Patients |
|
|
| Completed | 2 | 340 | RoW | GZR18, Placebo | Gan and Lee Pharmaceuticals, USA | Obesity, Overweight | 06/24 | 06/24 | | |
NCT06256549: A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus |
|
|
| Active, not recruiting | 2 | 272 | RoW | GZR18, Semaglutide | Gan and Lee Pharmaceuticals, USA | Type 2 Diabetes | 07/24 | 07/24 | | |
| Completed | 1/2 | 72 | RoW | GZR18, Placebo | Gan and Lee Pharmaceuticals, USA | Type 2 Diabetes | 09/23 | 09/23 | | |
| Completed | 1/2 | 60 | RoW | GZR18, Placebo | Gan and Lee Pharmaceuticals, USA | Obesity, Overweight | 10/23 | 10/23 | | |
NCT06548997: A Phase I Study of GZR18 Injection in Healthy Subjects |
|
|
| Completed | 1 | 57 | RoW | GZR18, Placebo | Gan and Lee Pharmaceuticals, USA | Type 2 Diabetes, Overweight and Obesity | 10/22 | 10/22 | | |
NCT06548945: A Phase I Study of GZR18 Injection in Obese/Overweight Subjects |
|
|
| Completed | 1 | 16 | RoW | GZR18, Placebo | Gan and Lee Pharmaceuticals, USA | Overweight and Obesity | 08/23 | 08/23 | | |
NCT04715529: Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers |
|
|
| Recruiting | 1 | 62 | RoW | FZJ-003, Placebo | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Healthy Volunteers | 05/23 | 06/23 | | |
NCT06176716: Phase 1 Hepatic Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride |
|
|
| Recruiting | 1 | 24 | RoW | ET-26 | Ahon Pharmaceutical Co., Ltd. | Hepatic Insufficiency | 03/24 | 04/24 | | |
| Hao, Chunyue |
NCT06202079: A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects With Type 2 Diabetes Mellitus |
|
|
| Completed | 2 | 179 | RoW | GZR4 Injection, Insulin Degludec | Gan and Lee Pharmaceuticals, USA | Diabetes Mellitus, Type 2 | 07/24 | 08/24 | | |
NCT06199505: A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects With T2DM |
|
|
| Enrolling by invitation | 2 | 150 | RoW | GZR101, insulin degledec/insulin aspart | Gan and Lee Pharmaceuticals, USA | Type 2 Diabetes | 08/24 | 09/24 | | |
NCT06547502: Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects With Renal Impairment |
|
|
| Recruiting | 1 | 28 | RoW | GZR4 | Gan and Lee Pharmaceuticals, USA | Diabetes | 10/24 | 10/24 | | |
